TY - JOUR
T1 - Real-world clinical responses in patients with type 2 diabetes mellitus adding exenatide BID (EBID) or mealtime insulin to basal insulin
T2 - a retrospective study using electronic medical record data
AU - Lang, Kathleen
AU - Nguyen, Hiep
AU - Huang, Huan
AU - Bauer, Elise
AU - Levin, Philip
N1 - Funding Information:
This study was funded by AstraZeneca.
Publisher Copyright:
© 2018 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018/6/3
Y1 - 2018/6/3
N2 - Aim: Exenatide twice daily (EBID) and mealtime insulin are effective add-on therapies to basal insulin for type 2 diabetes patients in clinical trials. This study used electronic medical record (EMR) data to evaluate analogous real-world clinical responses. Materials and methods: Adult patients initiating EBID or mealtime insulin as add-on to basal insulin during January 2008–March 2013 were identified in a US EMR database. EBID patients were propensity score matched 1:1 to mealtime insulin patients. Cohorts were followed for 12 months before (baseline) and 6 months after the index. A1C, hypoglycemic events, change in weight, and other clinical measures were evaluated by A1C attainment level (<6.5, < 7, < 7.5, <8, <9%) and baseline A1C. Results: In total, 1249 EBID patients were matched to 1249 mealtime insulin patients. During follow-up, the percentage reaching A1C levels was similar for EBID vs mealtime insulin cohorts for all attainment levels (<7%: 27.8% vs 24.2%; < 9%: 79.7% vs 79.2%; p = NS). The percentage reaching A1C < 7% was similar for both cohorts with different baseline A1C. EBID patients had less hypoglycemia at all attainment levels (3.1% vs 11.1% [<6.5%]; 2.5% vs 4.7% [<9%]; all p <.03) and more weight loss (–9.0 vs –3.2 lb [<6.5%]; –3.4 vs +0.8 lb [<9%]; all p <.01). Conclusions: EBID added to basal insulin was as effective in a real-world setting as mealtime insulin added to basal insulin in reducing A1C, with less weight gain and less hypoglycemia for a wide range of A1C attainment levels and baseline values.
AB - Aim: Exenatide twice daily (EBID) and mealtime insulin are effective add-on therapies to basal insulin for type 2 diabetes patients in clinical trials. This study used electronic medical record (EMR) data to evaluate analogous real-world clinical responses. Materials and methods: Adult patients initiating EBID or mealtime insulin as add-on to basal insulin during January 2008–March 2013 were identified in a US EMR database. EBID patients were propensity score matched 1:1 to mealtime insulin patients. Cohorts were followed for 12 months before (baseline) and 6 months after the index. A1C, hypoglycemic events, change in weight, and other clinical measures were evaluated by A1C attainment level (<6.5, < 7, < 7.5, <8, <9%) and baseline A1C. Results: In total, 1249 EBID patients were matched to 1249 mealtime insulin patients. During follow-up, the percentage reaching A1C levels was similar for EBID vs mealtime insulin cohorts for all attainment levels (<7%: 27.8% vs 24.2%; < 9%: 79.7% vs 79.2%; p = NS). The percentage reaching A1C < 7% was similar for both cohorts with different baseline A1C. EBID patients had less hypoglycemia at all attainment levels (3.1% vs 11.1% [<6.5%]; 2.5% vs 4.7% [<9%]; all p <.03) and more weight loss (–9.0 vs –3.2 lb [<6.5%]; –3.4 vs +0.8 lb [<9%]; all p <.01). Conclusions: EBID added to basal insulin was as effective in a real-world setting as mealtime insulin added to basal insulin in reducing A1C, with less weight gain and less hypoglycemia for a wide range of A1C attainment levels and baseline values.
KW - Exenatide
KW - basal insulin
KW - electronic medical record data
KW - mealtime insulin
UR - http://www.scopus.com/inward/record.url?scp=85042934126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042934126&partnerID=8YFLogxK
U2 - 10.1080/03007995.2018.1437027
DO - 10.1080/03007995.2018.1437027
M3 - Article
C2 - 29394878
AN - SCOPUS:85042934126
SN - 0300-7995
VL - 34
SP - 1045
EP - 1051
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
IS - 6
ER -